Sun Pharma to conduct clinical trial of pancreatitis drug in COVID-19 patients

Bengaluru: Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients. “Nafamostat (has been) identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany,” the company said in a statement. Click here to follow LIVE updates on coronavirus outbreak The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020. Shares of Sun Pharma rose 5 percent intraday on Friday after receiving approval from the Indian drug regulator for clinical trial of its drug on COVID-19 patients.